AguiarRAraújoCMartins-CoelhoGIsenbergD. Use of rituximab in systemic lupus erythematosus: A single center experience over 14 years. Arthritis Care Res (Hoboken)2017; 69: 257–262.
2.
HahnBH. Belimumab for systemic lupus erythematosus. N Engl J Med2013; 368: 1528–1535.
KraaijTHuizingaTWRabelinkTJTengYK. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford)2014; 53: 2122–2124.
5.
SimonettaFAllaliDRoux-LombardPChizzoliniC. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine2017; 84: 235–236.
6.
SaitoKNawataMIwataSTokunagaMTanakaY. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology (Oxford)2005; 44: 1462–1464.
7.
AlexanderTSarfertRKlotscheJet al.The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis2015; 74: 1474–1478.
8.
De VitaSQuartuccioLSalvinSet al.Sequential therapy with belimumab followed by rituximab in Sjögren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: Evidence for long-term efficacy. Clin Exp Rheumatol2014; 32: 490–494.
